Compare · ANCN vs FLXN
ANCN vs FLXN
Side-by-side comparison of Anchiano Therapeutics Ltd. (ANCN) and Flexion Therapeutics, Inc. (FLXN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANCN and FLXN operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- FLXN carries a market cap of $458.9M.
- FLXN has more recent analyst coverage (7 ratings vs 0 for ANCN).
- Company
- Anchiano Therapeutics Ltd.
- Flexion Therapeutics, Inc.
- Price
- -
- $25.60+0.16%
- Market cap
- -
- $458.9M
- 1M return
- -
- +2.03%
- 1Y return
- -
- +0.35%
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2014
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 7
Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Latest ANCN
- SEC Form 8-K/A filed by Anchiano Therapeutics Ltd.
- SEC Form 4: Ltd. Gp Israel Orbimed was granted 288,170 units of American Depository Shares
- SEC Form 4: Peter Thiel bought $0 worth of American Depositary Shares (230,536 units at $0.00)
- SEC Form 3: Peter Thiel claimed ownership of 877,973 units of American Depositary Shares
- Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing
- SEC Form 4 filed by Stanislav Polovets
- SEC Form 3 filed by Stanislav Polovets
- SEC Form 3 filed by Andrew Fine
- SEC Form 4 filed by Harris Neil Cohen
- SEC Form 3: Harris Neil Cohen claimed ownership of 62,110 units of Ordinary Shares
Latest FLXN
- Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer
- SEC Form 15-12B filed by Flexion Therapeutics, Inc.
- SEC Form EFFECT filed by Flexion Therapeutics, Inc.
- SEC Form 4 filed by Newtyn Management, Llc
- SEC Form 3: New insider Newtyn Management, Llc claimed ownership of 5,900,000 shares
- SEC Form 4: Stejbach Mark returned $107,364 worth of shares to the company (12,631 units at $8.50), closing all direct ownership in the company to cover taxes
- SEC Form 4: Milinazzo Alan returned $233,325 worth of shares to the company (27,450 units at $8.50), closing all direct ownership in the company to satisfy withholding tax
- SEC Form 4: Merrifield C Ann returned $161,500 worth of shares to the company (19,000 units at $8.50), closing all direct ownership in the company to cover withholding tax
- SEC Form 4: Lukatch Heath returned $76,500 worth of shares to the company (9,000 units at $8.50), closing all direct ownership in the company to satisfy tax liability
- SEC Form 4: Kwo Elizabeth returned $38,250 worth of shares to the company (4,500 units at $8.50), closing all direct ownership in the company (tax liability)